Advertisement
HIMS vs HROW
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HIMS is a Hold and HROW is a Hold.
HIMS's Indicator enters downward trend
The Aroon Indicator for HIMS entered a downward trend on September 22, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 217 similar instances where the Aroon Indicator formed such a pattern. In 190 of the 217 cases the stock moved lower. This puts the odds of a downward move at 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 53 of 62 cases where HIMS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HIMS as a result. In 66 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The Moving Average Convergence Divergence Histogram (MACD) for HIMS turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 33 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.
HIMS moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for HIMS crossed bearishly below the 50-day moving average on October 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HIMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
HIMS broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
Following a +3.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where HIMS advanced for three days, in 244 of 283 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. HIMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 74 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HIMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 76 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.704) is normal, around the industry mean (43.873). P/E Ratio (57.137) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (2.624) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.686) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
HROW's RSI Indicator descends into oversold zone
The RSI Oscillator for HROW moved into overbought territory on October 16, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +4.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where HROW advanced for three days, in 248 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
HROW may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HROW declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for HROW entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 67 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HROW’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (78.125) is normal, around the industry mean (43.873). P/E Ratio (39.526) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.270) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (4.627) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. HROW’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
HIMS | HROW | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 81 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 81 Overvalued | 78 Overvalued | |
PROFIT vs RISK RATING 1..100 | 74 | 67 | |
SMR RATING 1..100 | 97 | 99 | |
PRICE GROWTH RATING 1..100 | 62 | 85 | |
P/E GROWTH RATING 1..100 | 76 | 8 | |
SEASONALITY SCORE 1..100 | 50 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
HROW's Valuation (78) in the Pharmaceuticals Other industry is in the same range as HIMS (81) in the null industry. This means that HROW’s stock grew similarly to HIMS’s over the last 12 months.
HROW's Profit vs Risk Rating (67) in the Pharmaceuticals Other industry is in the same range as HIMS (74) in the null industry. This means that HROW’s stock grew similarly to HIMS’s over the last 12 months.
HIMS's SMR Rating (97) in the null industry is in the same range as HROW (99) in the Pharmaceuticals Other industry. This means that HIMS’s stock grew similarly to HROW’s over the last 12 months.
HIMS's Price Growth Rating (62) in the null industry is in the same range as HROW (85) in the Pharmaceuticals Other industry. This means that HIMS’s stock grew similarly to HROW’s over the last 12 months.
HROW's P/E Growth Rating (8) in the Pharmaceuticals Other industry is significantly better than the same rating for HIMS (76) in the null industry. This means that HROW’s stock grew significantly faster than HIMS’s over the last 12 months.
| HIMS | HROW | |
|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 90% |
| Stochastic ODDS (%) | 3 days ago 85% | 3 days ago 84% |
| Momentum ODDS (%) | 3 days ago 79% | N/A |
| MACD ODDS (%) | 3 days ago 72% | N/A |
| TrendWeek ODDS (%) | 3 days ago 82% | 3 days ago 81% |
| TrendMonth ODDS (%) | 3 days ago 87% | 3 days ago 83% |
| Advances ODDS (%) | 24 days ago 86% | 27 days ago 83% |
| Declines ODDS (%) | 5 days ago 82% | 5 days ago 79% |
| BollingerBands ODDS (%) | 3 days ago 74% | 3 days ago 83% |
| Aroon ODDS (%) | 3 days ago 88% | 3 days ago 83% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HIMS’s FA Score shows that 0 FA rating(s) are green while HROW’s FA Score has 1 green FA rating(s).
- HIMS’s FA Score: 0 green, 5 red.
- HROW’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HIMS’s TA Score shows that 1 TA indicator(s) are bullish while HROW’s TA Score has 4 bullish TA indicator(s).
- HIMS’s TA Score: 1 bullish, 8 bearish.
- HROW’s TA Score: 4 bullish, 2 bearish.
Price Growth
HIMS (@Pharmaceuticals: Generic) experienced а -9.22% price change this week, while HROW (@Pharmaceuticals: Generic) price change was -7.08% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -6.95%. For the same industry, the average monthly price growth was -5.23%, and the average quarterly price growth was +10.96%.
Reported Earning Dates
HIMS is expected to report earnings on Nov 09, 2026.
HROW is expected to report earnings on Nov 16, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-6.95% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SCHI | 21.61 | -0.03 | -0.14% |
| Schwab 5-10 Year Corporate Bond ETF (SCHI) | |||
| MSTB | 44.04 | -0.27 | -0.60% |
| LHA Market State Tactical Beta ETF (MSTB) | |||
| QSPT | 35.72 | -0.59 | -1.62% |
| FT Vest Nasdaq-100 Buffer ETF - September (QSPT) | |||
| ONLN | 57.09 | -1.40 | -2.40% |
| ProShares Online Retail ETF (ONLN) | |||
| CSCL | 48.87 | -2.38 | -4.64% |
| Direxion Daily CSCO Bull 2X ETF (CSCL) | |||
HIMS and
Correlation & Price change
A.I.dvisor tells us that HIMS and COTY have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HIMS and COTY's prices will move in lockstep.
| Ticker / NAME | Correlation To HIMS | 1D Price Change % | ||
|---|---|---|---|---|
| HIMS | 100% | -4.46% | ||
| COTY - HIMS | 31% Poorly correlated | +0.31% | ||
| HROW - HIMS | 25% Poorly correlated | -5.11% | ||
| IRWD - HIMS | 25% Poorly correlated | -7.16% | ||
| EVO - HIMS | 24% Poorly correlated | -2.82% | ||
| IPAR - HIMS | 24% Poorly correlated | +0.50% | ||
More | ||||
HROW and
Correlation & Price change
A.I.dvisor indicates that over the last year, HROW has been loosely correlated with AQST. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if HROW jumps, then AQST could also see price increases.
| Ticker / NAME | Correlation To HROW | 1D Price Change % | ||
|---|---|---|---|---|
| HROW | 100% | -5.11% | ||
| AQST - HROW | 35% Loosely correlated | -6.90% | ||
| AMRX - HROW | 29% Poorly correlated | -0.36% | ||
| AYTU - HROW | 28% Poorly correlated | -1.00% | ||
| RMTI - HROW | 27% Poorly correlated | -6.89% | ||
| TEVA - HROW | 27% Poorly correlated | +0.95% | ||
More | ||||